Skip to content

Effects of Fluid Therapy on Peripheral TIssse Perfusion During Sepsis/Septic Shock

Effects of Fluid Therapy on Peripheral TIssue Perfusion During Sepsis/Septic Shock

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05094856
Acronym
REPTILOS
Enrollment
61
Registered
2021-10-26
Start date
2022-02-23
Completion date
2023-03-16
Last updated
2024-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis, Septic Shock

Keywords

Endothelial dysfunction, Albumin, Fluid Therapy, Peripheral Tissue Perfusion, Septic shock, Microcirculatory effects, Hemodynamic effects, sepsis

Brief summary

Compare the effect of volume expansion by saline versus albumin on the correction of peripheral tissue hypoperfusion by measuring Index skin recoloration time (CRT) at H0 and H1

Detailed description

This is a transversal study allowing to compare the effect of volume expansion by saline versus albumin on the correction of peripheral tissue hypoperfusion Design: • A multicentric, open-label, transversal study Sample size : 60 patients Assessement: Between the admission to intensive care and 48 hours after admission, the patient will be included after collection of the non-opposition form. The patient will receive volume expansion either by 0.9% saline (500mL) or by 20% albumin (100mL) over 15 minutes. Repeated clinical measurements will be performed at H0, H0.5 and H1 (respectively at 0, 30 and 60 minutes). A blood sample will be taken just before the volume expansion and 4 hours after, at the same time as the samples usually taken as part of the treatment. No interim analysis is planned. Analysis will be performed at the end of the study after data review and freezing of data base.

Interventions

None listed

Sponsors

Grifols (funder)
CollaboratorUNKNOWN
Institut National de la Santé Et de la Recherche Médicale, France
CollaboratorOTHER_GOV
Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age\> 18 years old * Sepsis or * Septic shock within 24 hours of admission to intensive care with a stable dose of norepinephrine for at least 2 hours to maintain MAP\> 65mmHg * CRT index\> 3 seconds despite the initial resuscitation (administration of antibiotics, volume expansion by crystalloids of 20 mL / Kg, noradrenaline started) between the admission to intensive care and H48 from admission to intensive care * Non-opposition of the patient collected by the doctor in charge of the patient between H0 and H6 after admission if the patient is vigilant, otherwise a procedure for collecting non-opposition from relatives will be carried out with collection of the non-opposition of the patient once he is able to give it. * Affiliation to a social security regimen (excluding AME)

Exclusion criteria

* Patient COVID-19 (+) with respiratory impairment * Pregnant and lactating woman * Patient under Guardianship / Curatorship * Refusal to participate * CRT not evaluable (dark or damaged skin) * Moribund patient * Estimated life expectancy less than 1 month * Participation in another interventional research involving the human person or period of exclusion at the end of a previous research involving the human person

Design outcomes

Primary

MeasureTime frameDescription
Compare the effect of volume expansion by saline versus albumin on the correction of peripheral tissue hypoperfusion by measuring Index skin recoloration time (CRT) at H0 and H11 hourProportion of patients who normalized their cutaneous re-coloring time (CRT) measured at the index level, defined by a value \<3 seconds at H1. The clinical measurement method has been standardized in the participating departments and has been used for several years in clinical practice.

Secondary

MeasureTime frameDescription
CRT Measure4 hoursClinical tissue perfusion parameters will be measured clinically every 30 minutes, as usual in patients with septis/septic shock.
mottling score measure4 hoursClinical tissue perfusion parameters will be measured clinically every 30 minutes, as usual in patients with sepsis/septic shock.
Diuresis4 hoursClinical tissue perfusion parameters will be measured clinically every 30 minutes, as usual in patients with sepsis/septic shock.
Variations in cardiac flow4 hoursClinical tissue perfusion parameters will be measured clinically every 30 minutes, as usual in patients with sepsis/septic shock.
Variations in the biological parameters4 hoursVariations in the biological parameters between H0 and H4 will be analyzed from 5 ml of blood taken in addition, in accordance with the usual practice, in a sepsis/septic shock: * IL-6, IL-1b, Il-8, TNFa, IL-10 * Syndecan-1, heparan sulfat, hyaluronat * Circulating microparticles

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 7, 2026